Biogen Announces Reduced Price for ADUHELM® to Improve

The company to also implement cost-reduction measures. December 20, 2021 07:00 ET Biogen Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%.

Read the source article at Send Press Releases with GlobeNewswire
2021-12-20 02:00:00